Valiant Laboratories Ltd IPO

The company is subject to strict quality requirements, regular inspections and audits by its customers and any failure to comply with quality standards may lead to cancellation of existing and future orders and could negatively impact the company business, financial condition, results of operations and prospects it may impact the reputation as well.

The company does not have long-term agreements with its suppliers for raw materials and an inability to procure the desired quality, quantity of its raw materials in a timely manner and at reasonable costs, or at all, may have a negative impact on the business, results of operations, financial condition and cash flows.

If there are delays in setting up the Proposed Facility or if the costs of setting up and the possible time or cost overruns related to the Proposed Facility or the purchase of plant and machinery for the Proposed Facility are higher than expected, it could have a material adverse effect on its financial condition, results of operations and growth prospects.

The company's single product manufacturing company and any changes to the paracetamol API industry or the company product demand will adversely affect its revenues, financials and profitability.

The majority of its operative income is derived from the domestic market and any adverse developments in this market could adversely affect its business.

The company Manufacturing Facility is located in one geographic area and therefore, any localized social unrest, natural disaster or breakdown of services or any other natural disaster in and around Palghar, Maharashtra or any disruption in production at, or shutdown of, its manufacturing unit could have material adverse effect on the company business and financial condition.

The company is dependent on a few customers for a major part of the revenues. Further its do not enter into long-term arrangements with the customers and any failure to continue our existing arrangements could adversely affect its business and results of operations.

The company is in the process of expanding its operations and establishing a network of customers in a line of business where the company do not have a significant presence or prior experience. Any failure to expand into these new products could adversely affect its sales, financial condition, result of operations and cash flows.

The company is subject to government regulations and if its fail to obtain, maintain or renew the statutory and regulatory licenses, permits and approvals required to operate the company business, results of operations and cash flows may be adversely affected.

The objects of the Issue include funding working capital requirements of Valiant Advanced Sciences Private Limited, a wholly owned Subsidiary of the Company, which are based on certain assumptions and estimates.